An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
Status:
RECRUITING
Trial end date:
2028-04-30
Target enrollment:
Participant gender:
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory autoimmune diseases. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
Phase:
NA
Details
Lead Sponsor:
The First Affiliated Hospital of University of Science and Technology of China